Capricor Therapeutics Moves Forward with FDA Submission
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a pioneering biotechnology firm focused on developing innovative cell and exosome-based treatments for rare diseases, is taking significant strides in bringing deramiocel to patients suffering from Duchenne muscular dystrophy (DMD). The company has officially announced the commencement of its rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) targeted at obtaining approval for deramiocel, a novel therapeutic designed to treat all patients diagnosed with DMD cardiomyopathy.
Targeting Duchenne Muscular Dystrophy with Cutting-Edge Therapies
Linda Marbán, Ph.D., CEO of Capricor Therapeutics, expressed the excitement surrounding this development, stating, "This announcement marks an important step in the U.S. regulatory process towards potential BLA approval of deramiocel for the treatment of DMD. Obtaining approval would expedite the delivery of this first-in-class treatment to those who need it most, and we are eager to collaborate with the FDA throughout this procedure." This rolling submission is expected to be completed by the end of 2024, with the potential for the application to qualify for priority review as it seeks to address a serious medical condition that currently has no approved treatment options available.
The Promise of Deramiocel
Deramiocel (also known as CAP-1002) is derived from allogeneic cardiosphere-derived cells (CDCs). These cells have demonstrated powerful immunomodulatory, antifibrotic, and regenerative properties in various studies related to dystrophinopathies and heart failure. By producing extracellular vesicles called exosomes, CDCs can target macrophages to shift their expression profile, encouraging a healing rather than a pro-inflammatory response. With over 100 peer-reviewed publications and successful administration to more than 200 patients in clinical trials, deramiocel stands as a promising treatment avenue.
Regulatory Pathway and Designations
Deramiocel has already attained Orphan Drug Designation, and the regulatory framework for its approval is supported by the Regenerative Medicine Advanced Therapy (RMAT) designation. If approved, Capricor anticipates receiving a Priority Review Voucher (PRV) based on the previous rare pediatric disease designation, further enhancing the potential benefits of this groundbreaking treatment.
Understanding Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is a serious genetic disorder characterized by gradual muscular weakness and chronic inflammation affecting skeletal, cardiac, and respiratory muscles. This disease significantly impacts the quality of life and has a median mortality age of around 30 years. DMD affects approximately one in every 3,500 male births, amounting to an estimated 15,000 to 20,000 individuals in the U.S. alone. The underlying mechanism of DMD results from the inadequate production of functional dystrophin, a protein essential for muscle cell integrity, leading to cell damage and eventual death.
Capricor's Commitment to Innovative Treatments
At the forefront of Capricor Therapeutics' mission is advancing transformative therapies for individuals grappling with rare diseases. Their flagship product, deramiocel, remains in Phase 3 clinical trials for DMD. The company also utilizes its proprietary StealthX™ platform for the targeted delivery of therapeutics, including oligonucleotides and proteins, aiming to tackle a variety of conditions beyond DMD.
Future Aspirations and Goals
Capricor remains resolute in pushing the boundaries of science and innovation in the realm of biotechnology. With a strong emphasis on patient needs, the company's efforts focus not only on getting deramiocel approved but on expanding the horizons of its exosome technology to potentially address a myriad of diseases. This commitment underscores Capricor's vision of transforming lives through dedicated research and advancement in the field of medicine.
Frequently Asked Questions
What is deramiocel?
Deramiocel (CAP-1002) is a cell therapy derived from cardiosphere-derived cells (CDCs), designed to treat Duchenne muscular dystrophy and enhance muscle regeneration.
What is Duchenne muscular dystrophy?
Duchenne muscular dystrophy (DMD) is a genetic disorder that leads to progressive muscle weakness and degeneration, primarily affecting boys and leading to severe life impacts.
What are the key benefits of Capricor's BLA submission?
The BLA submission is a critical step towards obtaining FDA approval for deramiocel, which could provide a much-needed treatment option for DMD patients, filling a significant gap in current therapies.
How does deramiocel work?
Deramiocel exerts its effects by secreting extracellular vesicles that target macrophages, helping to switch their behavior towards a healing response, which is essential for combating inflammation and fibrosis.
What is Capricor's mission?
Capricor's mission is to revolutionize treatment for rare diseases through innovative cell and exosome-based therapeutics, ensuring that patients have access to groundbreaking therapies.
